Sling Therapeutics Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$123M
- Investors
-
4
Sling Therapeutics General Information
Description
Developer of a biopharmaceutical therapy designed to ease the treatment burden for thyroid eye disease patients. The company offers oral small-molecule therapy for the treatment of thyroid eye disease, enabling the ophthalmology and endocrinology communities to provide additional treatment options for autoimmune and rare diseases.
Contact Information
Website
www.slingtx.comCorporate Office
- 455 East Eisenhower Parkway
- Suite 300 PMB 109
- Ann Arbor, MI 48108
- United States
Corporate Office
- 455 East Eisenhower Parkway
- Suite 300 PMB 109
- Ann Arbor, MI 48108
- United States
Sling Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series C) | 16-Sep-2026 | $123M | Completed | Clinical Trials - Phase 3 | ||
| 2. Early Stage VC (Series A) | 13-Jun-2022 | Completed | Clinical Trials - Phase 2 | |||
| 1. Accelerator/Incubator | 01-Jan-2021 | Completed | Startup |
Sling Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C1 | ||||||||
| Series B1 | ||||||||
| Series A1 | 43,298,961 | $0.000001 | $0.81 | $0.81 | 1x | $0.81 | 10.46% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Sling Therapeutics Comparisons
Industry
Financing
Details
Sling Therapeutics Competitors (42)
One of Sling Therapeutics’s 42 competitors is Argos Therapeutics, a Venture Capital-Backed company based in Durham, NC.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Argos Therapeutics | Venture Capital-Backed | Durham, NC | ||||
| AnTolRx | Formerly VC-backed | Cambridge, MA | ||||
| Orchard Therapeutics | Formerly VC-backed | London, United Kingdom | ||||
| Altimmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Phaxiam | Formerly VC-backed | Lyon, France |
Sling Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Sling Therapeutics Patents
Sling Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026150308-A1 | Treatment of thyroid eye disease | Pending | 08-Jan-2025 | ||
| WO-2025155894-A1 | Use of inhibitors of insulin-like growth factor receptor-1 for fibrotic diseases | Pending | 19-Jan-2024 | ||
| WO-2025155896-A1 | Use of inhibitors of insulin-like growth factor receptor-1 for growth hormone igf-secreting neoplasias | Pending | 19-Jan-2024 | ||
| WO-2025155888-A1 | Use of inhibitors of insulin-like growth factor receptor-1 for ocular-associated disorders | Pending | 19-Jan-2024 | ||
| WO-2025007015-A2 | Use of inhibitors of insulin-like growth factor receptor-1 for multiple sclerosis | Inactive | 30-Jun-2023 | A61K31/4985 |
Sling Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Sling Therapeutics Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Forbion | Venture Capital | Minority | ||
| Sectoral Asset Management | Venture Capital | Minority | ||
| The Rise Fund | Impact Investing | Minority | ||
| TPG | PE/Buyout | Minority |
Sling Therapeutics FAQs
-
When was Sling Therapeutics founded?
Sling Therapeutics was founded in 2020.
-
Where is Sling Therapeutics headquartered?
Sling Therapeutics is headquartered in Ann Arbor, MI.
-
What is the size of Sling Therapeutics?
Sling Therapeutics has 10 total employees.
-
What industry is Sling Therapeutics in?
Sling Therapeutics’s primary industry is Drug Discovery.
-
Is Sling Therapeutics a private or public company?
Sling Therapeutics is a Private company.
-
What is the current valuation of Sling Therapeutics?
The current valuation of Sling Therapeutics is .
-
What is Sling Therapeutics’s current revenue?
The current revenue for Sling Therapeutics is .
-
How much funding has Sling Therapeutics raised over time?
Sling Therapeutics has raised $158M.
-
Who are Sling Therapeutics’s investors?
Forbion, Sectoral Asset Management, The Rise Fund, and TPG have invested in Sling Therapeutics.
-
Who are Sling Therapeutics’s competitors?
Argos Therapeutics, AnTolRx, Orchard Therapeutics, Altimmune, and Phaxiam are some of the 42 competitors of Sling Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
